196 related articles for article (PubMed ID: 30511296)
1. Treating psoriatic arthritis to target: discordance between physicians and patients' assessment, non-adherence, and restricted access to drugs precluded therapy escalation in a real-world cohort.
Ferreira MF; Kohem CL; Xavier RM; Abegg E; Martins OS; Resmini MB; de Mello AL; de Almeida Menegat F; Hax V; Gasparin AA; Brenol CV; de Andrade NPB; Viecceli D; Brenol JCT; Palominos PE
Clin Rheumatol; 2019 Mar; 38(3):961-968. PubMed ID: 30511296
[TBL] [Abstract][Full Text] [Related]
2. Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population.
Michelsen B; Diamantopoulos AP; Høiberg HK; Soldal DM; Kavanaugh A; Haugeberg G
J Rheumatol; 2017 Apr; 44(4):431-436. PubMed ID: 28148701
[TBL] [Abstract][Full Text] [Related]
3. Treating to target in psoriatic arthritis: assessing real-world outcomes and optimising therapeutic strategy for adults with psoriatic arthritis-study protocol for the MONITOR-PsA study, a trials within cohorts study design.
Rombach I; Tillett W; Jadon D; Tucker L; Watson M; Francis A; Sinomati Y; Eldridge L; Dritsaki M; Dutton SJ; Al-Mossawi H; Gullick N; Thompson B; Coates LC
Trials; 2021 Mar; 22(1):185. PubMed ID: 33663566
[TBL] [Abstract][Full Text] [Related]
4. Patient's Global Assessment as an Outcome Measure for Psoriatic Arthritis in Clinical Practice: A Surrogate for Measuring Low Disease Activity?
Lubrano E; Perrotta FM; Parsons WJ; Marchesoni A
J Rheumatol; 2015 Dec; 42(12):2332-8. PubMed ID: 26523033
[TBL] [Abstract][Full Text] [Related]
5. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
Perrotta FM; Marchesoni A; Lubrano E
J Rheumatol; 2016 Feb; 43(2):350-5. PubMed ID: 26669925
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort.
Lubrano E; De Socio A; Perrotta FM
J Rheumatol; 2017 Aug; 44(8):1159-1164. PubMed ID: 28572467
[TBL] [Abstract][Full Text] [Related]
7. Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study.
Queiro R; Cañete JD; Montilla C; Abad M; Montoro M; Gómez S; Cábez A;
Arthritis Res Ther; 2017 Mar; 19(1):72. PubMed ID: 28356155
[TBL] [Abstract][Full Text] [Related]
8. Results of one-year treat-to-target strategy in early psoriatic arthritis: data of an open-label REMARCA study.
Korotaeva TV; Loginova EY; Getiya TS; Nasonov EL
Ter Arkh; 2018 May; 90(5):22-29. PubMed ID: 30701886
[TBL] [Abstract][Full Text] [Related]
9. Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study.
Napolitano M; Costa L; Caso F; Megna M; Scarpa R; Balato N; Ayala F; Balato A
Clin Rheumatol; 2017 Jul; 36(7):1589-1593. PubMed ID: 28567556
[TBL] [Abstract][Full Text] [Related]
10. Discordance between tender and swollen joint count as well as patient's and evaluator's global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMARD study.
Michelsen B; Kristianslund EK; Hammer HB; Fagerli KM; Lie E; Wierød A; Kalstad S; Rødevand E; Krøll F; Haugeberg G; Kvien TK
Ann Rheum Dis; 2017 Apr; 76(4):708-711. PubMed ID: 27707730
[TBL] [Abstract][Full Text] [Related]
11. Burden of Psoriatic Arthritis According to Different Definitions of Disease Activity: Comparing Minimal Disease Activity and the Disease Activity Index for Psoriatic Arthritis.
Wervers K; Vis M; Tchetveriko I; Gerards AH; Kok MR; Appels CWY; van der Graaff WL; van Groenendael JHLM; Korswagen LA; Veris-van Dieren JJ; Hazes JMW; Luime JJ
Arthritis Care Res (Hoboken); 2018 Dec; 70(12):1764-1770. PubMed ID: 29609220
[TBL] [Abstract][Full Text] [Related]
12. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA).
Theander E; Husmark T; Alenius GM; Larsson PT; Teleman A; Geijer M; Lindqvist UR
Ann Rheum Dis; 2014 Feb; 73(2):407-13. PubMed ID: 23355078
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Response to Treatment, Remission, and Minimal Disease Activity in Axial Psoriatic Arthritis Treated with Tumor Necrosis Factor Inhibitors.
Lubrano E; Parsons WJ; Perrotta FM
J Rheumatol; 2016 May; 43(5):918-23. PubMed ID: 26980581
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of minimal disease activity in Australian patients with Psoriatic Arthritis: Assessing the outcome of national funding criteria for biologic disease-modifying antirheumatic drug prescribing.
Pontifex EK; Dissanayake K; Bursill D; Gill T
Int J Rheum Dis; 2019 Feb; 22(2):262-268. PubMed ID: 30450819
[TBL] [Abstract][Full Text] [Related]
15. Treat to target in psoriatic arthritis-evidence, target, research agenda.
Coates LC; Helliwell PS
Curr Rheumatol Rep; 2015 Jun; 17(6):517. PubMed ID: 25903668
[TBL] [Abstract][Full Text] [Related]
16. Ten years of follow-up data in psoriatic arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway.
Haugeberg G; Michelsen B; Tengesdal S; Hansen IJW; Diamantopoulos A; Kavanaugh A
Arthritis Res Ther; 2018 Aug; 20(1):160. PubMed ID: 30071892
[TBL] [Abstract][Full Text] [Related]
17. Management of rheumatoid arthritis in clinical practice using treat-to-target strategy: Where do we stand in the multi-ethnic Malaysia population?
Tan BE; Lim AL; Kan SL; Lim CH; Ng YF; Tng SLC; Hassin NS; Chandran L; Hamid NA; Lee YYL
Rheumatol Int; 2017 Jun; 37(6):905-913. PubMed ID: 28389855
[TBL] [Abstract][Full Text] [Related]
18. Psoriatic arthritis in Canadian clinical practice: the PsA assessment in rheumatology.
Gladman DD; Chandran V; Thavaneswaran A; Zummer M
J Rheumatol; 2012 Sep; 39(9):1850-3. PubMed ID: 22859361
[TBL] [Abstract][Full Text] [Related]
19. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
[TBL] [Abstract][Full Text] [Related]
20. Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries.
Gorlier C; Orbai AM; Puyraimond-Zemmour D; Coates LC; Kiltz U; Leung YY; Palominos P; Cañete JD; Scrivo R; Balanescu A; Dernis E; Tälli S; Ruyssen-Witrand A; Soubrier M; Aydin SZ; Eder L; Gaydukova I; Lubrano E; Kalyoncu U; Richette P; Husni ME; de Wit M; Smolen JS; Gossec L
Ann Rheum Dis; 2019 Feb; 78(2):201-208. PubMed ID: 30442648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
